Sanofi (NEOE:SAN) Beta: N/A (As of Jun. 27, 2026)


NEOE:SAN Sanofi SA NEOE:SAN
59 GF Score
Price C$9.35
GF Value C$13.32
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Sanofi Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Sanofi's Beta is Not available.

Sanofi  (NEOE:SAN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Sanofi Beta Related Terms

Sanofi Beta Historical Data

* Premium members only.

The historical data trend for Sanofi's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Beta Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NEOE:SAN
59GF Score
Sanofi SA NEOE:SAN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Sanofi (NEOE:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of C$9.35 is trading 29.8% below its estimated GF Value™ of C$13.32. GuruFocus considers Sanofi to be Possible Value Trap.

Key valuation signals for NEOE:SAN:

  • Beta: N/A
  • GF Value™: C$13.32 vs. price of C$9.35 (29.8% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the NEOE:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
59GF Score

Get the complete analysis for NEOE:SAN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.35
Price
C$13.32
GF Value